IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
Life review of elderly depression
Development and application of ATR-FTIR spectroscopy for mixture homogeneity in pharmaceutical application
The Increasing Damage in Tubular Cell of Infant Mice’s Kidneys from Carbofuran Exposure during its Mothers’ Lactation Period
Trend of transsexualism problem and its implications towards muslim community in Malaysia
Development and validation of RP-HPLC method for the estimation of pidotimod in tablet dosage form
Evaluation of neurotoxicity of the ethanolic bark extract of Holarrhena pubescens Wall. ex G.Don in mice
Design, synthesis and evaluation of 2-aminobenzimidazole derivatives: strong candidate for PPAR gamma agonists.
Prediction of Heart Disease Using Feature Selection and Random Forest Ensemble Method
Strategies for Antiviral Drugs from Plants by Targeting the Hemagglutinin, Neuraminidase and other receptors of Influenza A virus
The impact of human resource and quality management in health care: A Review
12345678910...
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Pharmacokinetic & Therapeutic Efficacy of Hydrocholorthiazide with Losartan in Treatment of Hypertension by LC-MS/MS

Author: GOUTAM MUKHOPADHYAY, SHYMODIP KUNDU, TRIPTI PAL, DEBASMITA MANNA, SAIKAT BHUNIA, PIYAL MAJUMDER, PAYAL JANA, ADITYA SARKAR
Abstract: Aims & Objectives: The main aim of the present research work is to evaluate the pharmacokinetic parameters as well as therapeutic efficacy of Hydrochlorothiazide along with Losartan used as a fixed dose combined drug in treatment of hypertension. Methods: This study is carried out by utilizing a typical two periods; randomized & two way complete cross over design. All the volunteers are received fixed dose and single dose product based on the randomization code in each clinical period. Then blood samples are taken and the comperative Pharmacokinetic study was carried out. Matrix effect for internal standard (Letrozole and Candesartan) and analytes (Losartan, LCA & HTCZ) were also carried out as per US-FDA guideline. Results and Discussion: Maximum plasma concentration of fixed dose combining drug (in which Losartan combined with HCTZ) was found 49±8.87 ng/ml (Cmax) at time 2.75±0.25hrs (tmax) for HCTZ and the average maximum plasma concentration of 6 volunteers was 49.87 ng/ml & Tmax 2.75hrs, AUC0-t was 227.02 ng/ml at 48 hrs and AUC0-a227.67 ng/ml at infinite time & plasma half life (T1/2) of HCTZ 4.91hrs and Ket value is 0.14hr-1. The matrix effect of internal standard (letrozole) ranged between 87.32% to 89.71% and for HCTZ it was between 88.47%-89.86%. And the matrix effect of internal standard (Candesartan) ranged between 93.77%-98.28% & same was found between 95.97%-96.78% in case of Losartan and for LCA it was 95.41%-98.39%. Conclusion: From the comperative pharmacokinetic study it can be concluded that after fixed dose combined drug treatment the maximum plasma concentration of losartan and losartan carboxylic acid were too much higher than the maximum concentration of losartan and LCA after single drug containing losartan only. And fixed dose combination drug is more susceptible than single dose of Losartan for the treatment of hypertension with better therapeutic efficacy.
Keyword: Fixed Dose, Pharmacokinetic study, LCA, Hypertension, Cmax, tmax, T1/2
DOI: https://doi.org/10.31838/ijpr/2020.12.04.027
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free